{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:49:13Z","timestamp":1792482553086,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40257-021-00625-4","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:03:35Z","timestamp":1626869015000},"page":"891-900","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020"],"prefix":"10.1007","volume":"22","author":[{"given":"Patrick M.","family":"Jedlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh F.","family":"Jedlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam T.","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"1\u20132","key":"625_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","volume":"33","author":"M Kasperkiewicz","year":"2007","unstructured":"Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33(1\u20132):67\u201377.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9863","key":"625_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332.","journal-title":"Lancet"},{"issue":"3","key":"625_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","volume":"73","author":"W Nishie","year":"2014","unstructured":"Nishie W. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. J Dermatol Sci. 2014;73(3):179\u201386.","journal-title":"J Dermatol Sci"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3389\/fimmu.2019.01238","volume":"10","author":"K Tasanen","year":"2019","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol. 2019;10:1238.","journal-title":"Front Immunol"},{"issue":"2","key":"625_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","volume":"155","author":"SG Lee","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155(2):172\u20137.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"625_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","volume":"184","author":"MSM Persson","year":"2021","unstructured":"Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study. Br J Dermatol. 2021;184(1):68\u201377.","journal-title":"Br J Dermatol"},{"issue":"8","key":"625_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","volume":"156","author":"SD Liu","year":"2020","unstructured":"Liu SD, Chen WT, Chi CC. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(8):891\u2013900.","journal-title":"JAMA Dermatol"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","volume":"5","author":"K Kridin","year":"2018","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"625_CR9","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.14649","volume":"32","author":"L Fania","year":"2018","unstructured":"Fania L, Di Zenzo G, Didona B, Pilla MA, Sobrino L, Panebianco A, et al. Increased prevalence of diabetes mellitus in bullous pemphigoid patients during the last decade. J Eur Acad Dermatol Venereol. 2018;32(4):e153\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"625_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40257-018-0400-7","volume":"20","author":"PM Jedlowski","year":"2019","unstructured":"Jedlowski PM, Te CH, Segal RJ, Fazel MT. Cutaneous adverse effects of diabetes mellitus medications and medical devices: a review. Am J Clin Dermatol. 2019;20(1):97\u2013114.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"625_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2337\/dc19-2424","volume":"43","author":"P Le","year":"2020","unstructured":"Le P, Chaitoff A, Misra-Hebert AD, Ye W, Herman WH, Rothberg MB. Use of antihyperglycemic medications in US adults: an analysis of the National Health and Nutrition Examination Survey. Diabetes Care. 2020;43(6):1227\u201333.","journal-title":"Diabetes Care"},{"key":"625_CR12","unstructured":"United Nations Department of Economic and Social Affairs PD. World population aging 2015. New York (NY): United Nations; 2015: p. 23\u201334."},{"issue":"15","key":"625_CR13","first-page":"224","volume":"10","author":"MJ Verheyden","year":"2020","unstructured":"Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;10(15):224.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"625_CR14","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.2337\/dc18-0210","volume":"41","author":"M Arai","year":"2018","unstructured":"Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese Adverse Drug Event Report Database. Diabetes Care. 2018;41(9):e130\u20132.","journal-title":"Diabetes Care"},{"issue":"11","key":"625_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/14740338.2019.1668373","volume":"18","author":"C Carnovale","year":"2019","unstructured":"Carnovale C, Mazhar F, Arzenton E, Moretti U, Pozzi M, Mosini G, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic\/pharmacokinetic assessment through an analysis of the vigibase(R). Expert Opin Drug Saf. 2019;18(11):1099\u2013108.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"625_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J B\u00e9n\u00e9","year":"2016","unstructured":"B\u00e9n\u00e9 J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case\u2013noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016;175(2):296\u2013301.","journal-title":"Br J Dermatol"},{"issue":"2","key":"625_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s11096-020-01003-6","volume":"42","author":"JA Molina-Guarneros","year":"2020","unstructured":"Molina-Guarneros JA, Sainz-Gil M, Sanz-Fadrique R, Garcia P, Rodriguez-Jimenez P, Navarro-Garcia E, et al. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases. Int J Clin Pharm. 2020;42(2):713\u201320.","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"625_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ijd.14658","volume":"59","author":"A Reolid","year":"2020","unstructured":"Reolid A, Munoz-Aceituno E, Rodriguez-Jimenez P, Gonzalez-Rojano E, Llamas-Velasco M, Fraga J, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a case series and analysis of cases reported in the Spanish pharmacovigilance database. Int J Dermatol. 2020;59(2):197\u2013206.","journal-title":"Int J Dermatol"},{"issue":"8","key":"625_CR19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"Douros A, Rouette J, Yin H, Yu OHY, Filion KB, Azoulay L. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes. Diabetes Care. 2019;42(8):1496\u2013503.","journal-title":"Diabetes Care"},{"issue":"10","key":"625_CR20","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/jdv.14312","volume":"31","author":"B Sim","year":"2017","unstructured":"Sim B, Fook-Chong S, Phoon YW, Koh HY, Thirumoorthy T, Pang SM, et al. Multimorbidity in bullous pemphigoid: a case-control analysis of bullous pemphigoid patients with age- and gender-matched controls. J Eur Acad Dermatol Venereol. 2017;31(10):1709\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"625_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case\u2013non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"issue":"6","key":"625_CR22","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78(6):1090\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"625_CR23","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","volume":"79","author":"O Varpuluoma","year":"2018","unstructured":"Varpuluoma O, Forsti AK, Jokelainen J, Turpeinen M, Timonen M, Tasanen K, et al. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study. J Am Acad Dermatol. 2018;79(6):1034-8.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"625_CR24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","volume":"154","author":"K Kridin","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018;154(10):1152\u20138.","journal-title":"JAMA Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00625-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T08:08:31Z","timestamp":1635926911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00625-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00625-4","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"28 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding was used for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Patrick M. Jedlowski, Mahdieh F. Jedlowski, and Maryam T. Fazel have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by PJ. PJ, MJ, and MF wrote the first draft of the manuscript and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}